Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test

被引:28
作者
Gutierrez-Galhardo, Maria C. [1 ]
Zancope-Oliveira, Rosely M. [2 ]
Monzon, Araceli [3 ]
Rodriguez-Tudela, Juan L. [3 ]
Cuenca-Estrella, Manuel [3 ]
机构
[1] Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Serv Infectol, BR-21045900 Rio De Janeiro, Brazil
[2] Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Lab Micol, BR-21045900 Rio De Janeiro, Brazil
[3] Inst Salud Carlos III, Ctr Nacl Microbiol, Dept Mycol, Madrid, Spain
关键词
E-test; growth phases; amphotericin B; itraconazole; AMPHOTERICIN-B; ITRACONAZOLE; VORICONAZOLE; YEAST;
D O I
10.1111/j.1439-0507.2009.01701.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>The susceptibility profile of 91 Sporothrix schenckii isolates in both growth phases was determined by microdilution test (Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing; AFST-EUCAST). Amphotericin B (AMB), itraconazole (ITC), posaconazole, ravuconazole and terbinafine were found active in vitro against both phases but minimum inhibitory concentrations values for mycelial phase were significantly higher. Fluconazole (FLC) and voriconazole (VRC) were inactive in vitro against both phases. The E-test technique was also performed with 41 representative isolates for AMB, FLC, ITC and VRC. Average agreement rates between yeast phase microdilution results and E-test results were high for AMB (77.5%) and FLC (87.8%), but low for ITC and VRC with rates of 56.4% and 54.5%, respectively. AFST-EUCAST is not the most recommended test to perform drug susceptibility testing of S. schenckii in clinical laboratories, and E-test could be an alternative methodology for this purpose, mainly when the activity in vitro of antifungal agents of AMB and FLC are evaluated.
引用
收藏
页码:227 / 231
页数:5
相关论文
共 10 条
[1]   In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods [J].
Alvarado-Ramirez, Eidi ;
Torres-Rodriguez, Josep M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (07) :2420-2423
[2]   Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species [J].
Chryssanthou, E ;
Cuenca-Estrella, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3841-3844
[3]   Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species [J].
Cuenca-Estrella, M ;
Lee-Yang, W ;
Ciblak, MA ;
Arthington-Skaggs, BA ;
Mellado, E ;
Warnock, DW ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3644-3647
[4]  
Ghosh A, 2001, INDIAN J MED RES, V113, P214
[5]   In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi [J].
González, GM ;
Fothergill, AW ;
Sutton, DA ;
Rinaldi, MG ;
Loebenberg, D .
MEDICAL MYCOLOGY, 2005, 43 (03) :281-284
[6]   Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of America [J].
Kauffman, Carol A. ;
Bustamante, Beatriz ;
Chapman, Stanley W. ;
Pappas, Peter G. .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (10) :1255-1265
[7]   In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine:: comparison of yeast and mycelial forms [J].
Kohler, Lidiane Meire ;
Soares, Betania Maria ;
Santos, Daniel de Assis ;
Da Silva Barros, Maria Elisabete ;
Hamdan, Junia Soares .
CANADIAN JOURNAL OF MICROBIOLOGY, 2006, 52 (09) :843-847
[8]  
McGinnis MR, 2001, MED MYCOL, V39, P369, DOI 10.1080/mmy.39.4.369.371
[9]   In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases [J].
Trilles, L ;
Fernandez-Torres, B ;
Lazéra, MD ;
Wanke, B ;
Schubach, AD ;
Paes, RD ;
Inza, I ;
Guarro, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3952-3954
[10]   Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome [J].
Wheat, LJ ;
Connolly, P ;
Smedema, M ;
Brizendine, E ;
Hafner, R .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) :1910-1913